Latest Product Development News

Betr Entertainment Limited reported a robust 25% headline turnover growth in Q2 FY26 despite a $13.2 million EBITDA loss in H1 due to customer-friendly racing outcomes and strategic investments. The company targets a positive EBITDA turnaround in H2 FY26 and FY27, supported by organic growth, Sky Racing integration, and a new share buyback program.

MONEYME has reported a robust second quarter with a 26% increase in its loan book to $1.75 billion and a 19% rise in revenue to $60 million, underpinned by improved credit quality and strategic funding initiatives.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.

INOVIQ Limited has completed a $10.2 million capital raise to accelerate development of its exosome-based ovarian cancer screening test and CAR-exosome therapeutics, alongside key leadership appointments and promising preclinical results.

NOVONIX is ramping up industrial-grade synthetic graphite production with mass manufacturing slated for 2026, while battery-grade output for Panasonic faces delays until late 2027. The company also navigates a major offtake termination and secures significant funding to support its growth.

Doctor Care Anywhere reported steady consultation growth and a third consecutive quarter of positive cashflow in Q4 2025, while advancing digital health pilots and reaffirming ambitious medium-term revenue and profitability goals.

icetana Limited reported steady growth in Q2 FY26 with a 36% increase in annual recurring revenue and expanded partnerships across APAC and the Middle East. The company’s cash flow improved, while product enhancements aim to strengthen its AI security offerings.

ikeGPS Group has reported a robust 35% increase in its platform subscription revenue exit run rate for the nine months to December 2025, reaffirming its FY26 growth guidance amid strong market demand and new AI-driven product launches.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.

AnteoTech has raised A$3.5 million through a discounted share placement to accelerate commercialisation of its advanced battery and life sciences technologies globally. The capital injection supports strategic partnerships and sales expansion in key markets including the US and India.

Elsight Limited capped 2025 with record quarterly revenue and a substantial US$21.2 million contract, signalling robust growth and expanding global defence engagements heading into 2026.